T ranscatheter aortic valve implantation (TAVI) has emerged as an alternative to surgery therapy for severe aortic stenosis. 1, 2 The detrimental impact of baseline chronic kidney disease (CKD) on worsening the prognosis of patients undergoing surgical aortic valve replacement is well established. 3, 4 Conversely, this remains a debated issue in patients undergoing TAVI.
Renal Dysfunction Impacts on TAVI Outcomes
for articles published from April 2002 (first-in-human TAVI date) until November 2014. Studies were identified using the major medical subject headings transcatheter aortic valve implantation OR transcatheter aortic valve replacement OR TAVI OR TAVR combined with the following text and keywords: renal function OR renal dysfunction OR renal failure OR chronic kidney disease OR CKD. Citations were screened at the title and abstract level by 2 independent reviewers, and retrieved as a full text if they reported data on outcomes after TAVI. No language limitations were applied. The full texts and bibliography of all potential articles were also retrieved in detail to look for additional relevant items.
Eligibility Criteria
Studies were included if reporting on outcomes after TAVI in patients with preoperative CKD (defined according to the estimation of glomerular filtration rate), and were excluded if any of the following criteria applied: (1) duplicate publication; (2) lack of data on CKD pre-TAVI; and (3) the outcome of interest was not clearly reported or could not be derived from the published results.
Data Extraction
Two reviewers independently screened the articles for eligibility. The reviewers compared the selected studies and any discrepancy was resolved by consensus.
Study End Points
The primary end point was 1-year all-cause mortality. Secondary end points of interest included: early (≤30 days) all-cause mortality, early and 1-year cardiovascular mortality, stroke, bleeding (major or lifethreatening), acute kidney injury (AKI), AKI 2 to 3, need for postprocedural dialysis, in-hospital length of stay, and contrast medium administration.
Statistical Analysis
The number of events, participants, means, SDs, and percentages were abstracted. Estimates of effect were calculated with a randomeffects model and confirmed by a fixed-effects model and expressed as odds ratio (OR) or mean difference (MD). Statistical significance
WHAT IS KNOWN
• The detrimental impact of chronic kidney disease (CKD) on prognosis is well-established for surgical aortic valve replacement, but not for those undergoing transcatheter aortic valve implantation.
• Prior studies suggest that severe CKD (stage 4 and 5)
is a predictor of early and late mortality in transcatheter aortic valve implantation patients.
WHAT THE STUDY ADDS
• This study observed that patients with stage 3 CKD, in addition to those with severe CKD, experience worse outcomes after transcatheter aortic valve implantation.
• Preoperative CKD (stages 3-5) significantly increases early and 1-year mortality, early stroke, and acute kidney injury including the need for dialysis.
• There is the need for studies on risk stratification, prevention strategies and postoperative management of transcatheter aortic valve implantation patients with CKD. Figure 1 . Flow diagram. Studies included in the quantitative synthesis. Renal Dysfunction Impacts on TAVI Outcomes was set at P≤0.05 (2-tailed) . Heterogeneity was assessed by Qstatistic and I 2 tests. Significant heterogeneity was considered present for P values <0.10 or I 2 >50%. In case of significant heterogeneity, the random-effects model was prioritized over the fixed-effects model and subgroup and sensitivity analyses were performed to explore sources of inconsistency. Meta-regressions were performed to test the influence of baseline characteristics as potential effect modifiers (significance at P≤0.05). Publication bias was assessed using funnel plots, the Egger test and the Trim and Fill method. All data analyses were performed using the Reviewer Manager Version 5.2 and the Prometa Software Version 2. [14] [15] [16] 
Results
Of 210 articles identified by the initial search, 43 were retrieved for more detailed evaluation, and 9 studies were included in the meta-analysis ( Figure 1 ). [10] [11] [12] [13] [17] [18] [19] [20] [21] The characteristics of the included studies are reported in Table 1 . There was no significant variability in the CKD definitions used across the studies.
All-Cause Mortality
Early all-cause mortality was significantly increased in patients with preoperative CKD stages 3 to 5 compared with stages 1 to 2 (7 studies including 4797 patients; OR, 1.44; 95% confidence interval [CI], 1.08-1.94; P=0.01), in stages 4 to 5 compared with stages 1 to 2 (5 studies; 2300 patients; OR, 2.31; 95% CI, 1.61-3.31; P<0.00001), in stage 3 compared with stages 1 to 2 (5 studies; 3881 patients; OR, 1.43; 95% CI, Figure 2 ).
One-year all-cause mortality (primary end point) was significantly increased in patients with preoperative CKD stages 3 to 5 compared with stages 1 to 2 (6 studies; 4421 patients; OR, 1.66; 95% CI, 1.23-2.25; P=0.001), in stages 4 to 5 compared with stages 1 to 2 (5 studies; 2300 patients; OR, 2.56; 95% CI, 1.54-4.24; P=0.0003), in stage 3 compared with stages 1 to 2 (5 studies; 3881 patients; OR, 1.41; 95% CI, 1.13-1.74; P=0.002) and in stages 4 to 5 compared with stage 3 (5 studies; 2568 patients; OR, 1.69; 95% CI, 1.20-2.38; P=0.003; Tables 2-5; Figure 3 ).
Cardiovascular Mortality
Early cardiovascular mortality was significantly increased in patients with preoperative CKD stages 3 to 5 compared with stages 1 to 2 (3 studies; 1576 patients; OR, 1.66; 95% CI, 1.04-2.67; P=0.03), and in stages 4 to 5 compared with stages 1 to 2 (2 studies; 688 patients; OR, 2.24; 95% CI, 1.11-4.52; P=0.02), but not significantly in stage 3 compared with stages 1 to 2 (2 studies; 1128 patients; OR, 1.49; 95% CI, 0.87-2.56; P=0.15) nor in stages 4 to 5 compared with stage 3 (2 studies; 796 patients; OR, 1.45; 95% CI, 0.80-2.61; P=0.22; Tables 2-5; Figure SI in the Data Supplement).
One-year cardiovascular mortality was significantly increased in patients with preoperative CKD stages 3 to 5 compared with stages 1 to 2 (2 studies; 2439 patients; OR, 1.32; 95% CI, 1.06-1.63; P=0.01), and in stages 4 to 5 compared with stages 1 to 2 (2 studies; 1296 patients; OR, 1.88; 95% CI, 1.20-2.92; P=0.005), but not significantly in stage 3 compared with stages 1 to 2 (2 studies; 2165 patients; OR, 1.22; 95% CI, 0.97-1.53; P=0.08) nor in stages 4 to 5 compared with stage 3 (2 studies; 1417 patients; OR, 1.75; 95% CI, 0.96-3.21; P=0.07; Tables 2-5; Figure SII in the Data Supplement). 
Table 2. Outcomes After Transcatheter Aortic Valve Implantation in Patients With Preoperative CKD 3 to 5 vs CKD 1 to 2

Acute Kidney Injury
Early AKI was significantly increased in patients with preoperative CKD stages 3 to 5 compared with stages 1 to 2 (6 studies; 3937 patients; OR, 
AKI Stages 2 to 3
Early AKI 2 to 3 was significantly increased in patients with preoperative CKD stages 3 to 5 compared with stages 1 to 2 ( Figure  SVII in the Data Supplement).
Length of Stay
In-hospital length of stay was significantly longer in patients with preoperative CKD stages 3 to 5 compared with stages 1 to 2 (2 studies; 963 patients; MD, 0.88; 95% CI, −0.00 to 1.75; P=0.05), but not in stages 4 to 5 compared with stages 1 to 2 (2 studies; 461 patients; MD, 0.83; 95% CI, −2.06 to 3.71; P=0.58), nor in stage 3 compared with stages 1 to 2 (2 studies; 879 patients; MD, 0.83; 95% CI, −0.14 to 1.81; P=0.09), nor in stages 4 to 5 compared with stage 3 (2 studies; 586 patients; MD, 0.08; 95% CI, −3.81 to 3.98; P=0.97; Tables 2-5; Figure  SVIII in the Data Supplement). 
Meta-Regression and Sensitivity Analysis
The primary end point of 1-year all-cause mortality was influenced by the following baseline characteristics: prior coronary artery bypass graft (CKD 3-5 versus 1-2, P=0.012; CKD 3 versus 1-2, P=0.021), prior myocardial infarction (CKD 3-5 versus 1-2, P=0.030), prior percutaneous coronary intervention (CKD 3-5 versus 1-2, P=0.035), logEuroSCORE (CKD 3-5 versus 1-2, P=0.005; CKD 3 versus 1-2, P=0.033), diabetes mellitus (CKD 4-5 versus 1-2, P=0.019) and hypertension (CKD 4-5 versus 1-2, P=0.050; CKD 4-5 versus 3, P=0.014). The significant increase of 1-year all-cause mortality was confirmed for CKD 3 to 5 versus CKD 1 to 2, CKD 4 to 5 versus CKD 1 to 2 and CKD 3 versus 1 to 2 comparisons when meta-analyses were repeated removing 1 study at the time (Tables I-III One-year all-cause mortality. Early random effects odds ratio and 95% confidence interval (CI) for 1-year all-cause mortality according to chronic kidney disease (CKD) stages. M-H indicates Mantel-Haenszel. Renal Dysfunction Impacts on TAVI Outcomes of all the end points with the exception of early cardiovascular mortality for the comparison between CKD 3 to 5 and CKD 1 to 2 (2 of 3 studies trimmed; OR, 1.50; 95% CI, 0.98-2.29; P=0.06; Table 2 ), and stroke (2 of 5 studies trimmed; OR, 1.43; 95% CI, 0.92-2.22; P=0.10; Table 5 ) and AKI 2 to 3 (1 of 4 studies trimmed; OR, 1.67; 95% CI, 0.97-2.86; P=0.06; Table 5 ) for the comparison between CKD 4 to 5 and CKD 3, which lost the statistical significance while maintaining similarly sized directional estimate effects.
Discussion
This meta-analysis, including 4992 patients treated with TAVI, adds to the current knowledge with the following considerations: (1) CKD (stages 3-5) is associated with significant increases of early and 1-year all-cause and cardiovascular mortality, early stroke, AKI, AKI 2 to 3, need for dialysis, and length of stay in the absence of differences in contrast medium administration; (2) compared with lower degree of CKD, worse renal impairment (ie, 4-5 versus 1-2; 4-5 versus 3; 3 versus 1-2) is associated with increased all-cause and cardiovascular mortality, stroke, AKI, AKI 2 to 3, need for dialysis and bleeding; and (3) CKD stage 3 significantly impacts on all-cause mortality, stroke, and AKI. These data in aggregate suggest that not only patients with severe CKD may experience worse outcomes after TAVI but also those with a moderate degree of renal impairment.
Preprocedural CKD has emerged as predictor of worse outcome after TAVI. In particular, the higher risk of mortality has been suggested in patients with more severe CKD. [10] [11] [12] 17, 20 However, recent data showed that advanced CKD (stages 4-5), but not moderate CKD (stage 3), was a predictor of early and late mortality. 10, 11 In contrast, other studies did not find a significant relationship between CKD and worse outcomes. 8, 9, 12, 13 Consistent with this background, in the present study, we pooled the available evidence on this issue confirming the negative prognostic impact of advanced CKD, but also demonstrating for the first time that CKD stage 3 is associated with a significant increase of early and late mortality. Frequently, patients with CKD, particularly those at an advanced stage of disease, have more cardiovascular risk factors and experience increased cardiovascular mortality. 10, 22 Given that severe aortic stenosis is per se also associated with other cardiac diseases negatively impacting on prognosis (coronary arterial disease, heart failure and arrhythmias), the presence of CKD may be responsible for an additional risk of cardiovascular mortality. In our study, all-cause mortality in patients with CKD was significantly increased and was related to increased cardiovascular mortality as well as a higher risk of stroke, bleeding (CKD 4-5), AKI (particularly severe AKI 2-3) and the need for postprocedural dialysis.
Few studies provided data on length of hospitalization, which in the pooled analysis resulted significantly longer in patients with CKD compared with those without. On the other hand, no significant differences in length of hospital stay emerged in the comparisons across CKD subgroups, which may reflect the small amount of data available and, possibly, a power issue.
Importantly, the increase of adverse outcomes associated with the presence of preoperative CKD, including AKI, AKI 2 to 3 and dialysis, was not potentially justified from differences in the contrast medium administration across different subgroups. Indeed, the absence of difference in contrast medium administration corroborates the result of the present meta-analysis. This was further reinforced by the observed persistence of increased 1-year all-cause mortality with more advanced stages of CKD (relative to stage 1-2) in multiple sensitivity analyses.
Altogether, these results could be of particular interest adding new insights into the concerns emerged on performing TAVI in patients with severe CKD, 10,17 also given that these patients were excluded from pivotal randomized trials. 1, 2 However, other data demonstrate that these patients may still benefit from the TAVI procedure because of improvement in functional status (New York Heart Association class) and absence of valve hemodynamic anomalies. 10 Further studies are needed to address this issue by better risk stratification facilitating the proper decision-making for such challenging patients. On the other hand, it should also be considered that some data report an improvement in renal function after TAVI suggesting that, although associated with increased mortality, TAVI might not be precluded to all patients with preoperative CKD. 12, [23] [24] [25] The results of this meta-analysis are affected by limitations and differences of the original included studies themselves. All meta-analyses share limitations related to differences in study design, end point definitions and publication bias. Patient-level data from TAVI studies prospectively reporting on CKD could be of added value to confirm our finding and further elucidate this topic. Because of incomplete/unequal reporting of data, not all the studies were available for pooled analyses of certain outcomes, which could lead to a potential publication bias. Finally, a longer follow-up (>1 year) is not available to date for the majority of the included studies.
Conclusions
Moderate and severe preoperative CKD significantly worsen the early and the late prognosis of patients undergoing TAVI. The results of the present meta-analysis should be considered hypothesis-generating for future studies on risk evaluation, prevention strategies and postoperative management.
